Cancer targeted drug delivery using active low-density lipoprotein nanoparticles encapsulated pyrimidines heterocyclic anticancer agents as microtubule inhibitors

References

• Abdellatif AAH. (2020). A plausible way for excretion of metal nanoparticles via active targeting. Drug Dev Ind Pharm 46:744–50.
   PubMed Web of Science ®Google Scholar
• Abdellatif AAH, Alturki H, Tawfeek HM. (2021). Different cellulosic polymers for synthesizing silver nanoparticles with antioxidant and antibacterial activities. Sci Rep 11:84. https://doi.org/10.1038/s41598-020-79834-6.
   PubMed Web of Science ®Google Scholar
• Abdellatif KRA, Bakr RB. (2021). Pyrimidine and fused pyrimidine derivatives as promising protein kinase inhibitors for cancer treatment. Med Chem Res 30:31–49. https://doi.org/10.1007/s00044-020-02656-8.
   Web of Science ®Google Scholar
• Abdellatif AA, Zayed G, El-Bakry A, et al. (2016). Novel gold nanoparticles coated with somatostatin as a potential delivery system for targeting somatostatin receptors. Drug Dev Ind Pharm 42:1782–91.
   PubMed Web of Science ®Google Scholar
• Adileh A, Setareh M, Mahsa T, Alireza F. (2021). Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy. Eur J Med Chem 221:113523.
   PubMed Web of Science ®Google Scholar
• Alhadad LJ, Harisa GI, Alanazi FK. (2020). Design and encapsulation of anticancer dual HSP27 and HER2 inhibitor into low density lipoprotein to target ovarian cancer cells. Saudi Pharm J 28:387–96.
   PubMed Web of Science ®Google Scholar
• Al-Jamal WT, Kostarelos K. (2011). Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res 44:1094–104.
   PubMed Web of Science ®Google Scholar
• Antalis CJ, Arnold T, Rasool T, et al. (2010). High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Res Treat 122:661–70.
   PubMed Web of Science ®Google Scholar
• Aziz MA, Serya RA, Lasheen DS, et al. (2016). Discovery of potent VEGFR-2 inhibitors based on furopyrimidine and thienopyrimidne scaffolds as cancer targeting agents. Sci Rep 6:24460.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Arnst KE, Wang Y, et al. (2018). Heterocyclic-fused pyrimidines as novel tubulin polymerization inhibitors targeting the colchicine binding site: structural basis and antitumor efficacy. J Med Chem 61:1704–18.
   PubMed Web of Science ®Google Scholar
• Behbehani H, Ibrahim HM, Makhseed S, et al. (2012). 2-Aminothiophenes as building blocks in heterocyclic synthesis: synthesis and antimicrobial evaluation of a new class of pyrido[1,2-a]thieno[3,2-e]pyrimidine, quinoline and pyridin-2-one derivatives. Eur J Med Chem 52:51–65.
   PubMed Web of Science ®Google Scholar
• Bildstein L, Dubernet C, Couvreur P. (2011). Prodrug-based intracellular delivery of anticancer agents. Adv Drug Deliv Rev 63:3–23.
   PubMed Web of Science ®Google Scholar
• Browning KL, Lind TK, Maric S, et al. (2017). Human lipoproteins at model cell membranes: effect of lipoprotein class on lipid exchange. Sci Rep 7:7478. https://doi.org/10.1038/s41598-017-07505-0
   PubMed Web of Science ®Google Scholar
• Chao W, Xianhao Z, Haoyu J, et al. (2021). Transporting mitochondrion-targeting photosensitizers into cancer cells by low-density lipoproteins for fluorescence-feedback photodynamic therapy. Nanoscale 13:1195–205. https://doi.org/10.1039/D0NR07342C
   PubMed Web of Science ®Google Scholar
• Daniel AB, Jennifer TS, Angela MZ, et al. (2011). Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures. ACS Nano 5:42–57. https://doi.org/10.1021/nn103098m
   PubMed Web of Science ®Google Scholar
• Davies NG, Browne H, Davis B, et al. (2012). Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization. Bioorg Med Chem 20:6770–89.
   PubMed Web of Science ®Google Scholar
• Dawood DH, Abbas EMH, Farghaly TA, et al. (2019). ZnO nanoparticles catalyst in the synthesis of bioactive fused pyrimidines as anti-breast cancer agents targeting VEGFR-2. Med Chem 15:277–86.
   PubMed Web of Science ®Google Scholar
• Edmondson R, Adcock AF, Yang L. (2016). Influence of matrices on 3D-cultured prostate cancer cells’ drug response and expression of drug-action associated proteins. PLOS One 11:e0158116. PMID: 27352049.
   PubMedGoogle Scholar
• El Sayed HE, Laila FA, Mohamed T, et al. (2020). Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology. Bioorg Chem 96:103616. https://doi.org/10.1016/j.bioorg.2020.103616.
   PubMed Web of Science ®Google Scholar
• Gallagher EJ, Zelenko Z, Neel BA, et al. (2017). Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia. Oncogene 36:6462–71.
   PubMed Web of Science ®Google Scholar
• Gunasekera UA, Pankhurst QA, Douek M. (2009). Imaging applications of nanotechnology in cancer. Target Oncol 4:169–81. https://doi.org/10.1007/s11523-009-0118-9
   PubMed Web of Science ®Google Scholar
• Harisa GI, Alanazi FK. (2014). Low density lipoprotein bionanoparticles: from cholesterol transport to delivery of anti-cancer drugs. Saudi Pharm J 22:504–15.
   PubMed Web of Science ®Google Scholar
• Huajian G, Wendong S, Lambert BF. (2005). Mechanics of receptor-mediated endocytosis. PNAS 102:9469–74. https://doi.org/10.1073/pnas.0503879102.
   PubMed Web of Science ®Google Scholar
• Huang H, William C, Juan C, Gang Z. (2015). Learning from biology: synthetic lipoproteins for drug delivery. WIREs Nanomed Nanobiotechnol 7:298–314.
   Google Scholar
• Huntosova V, Buzova D, Petrovajova D, et al. (2012). Development of a new LDL-based transport system for hydrophobic/amphiphilic drug delivery to cancer cells. Int J Pharm 436:463–71.
   PubMedGoogle Scholar
• Ibrahim SAE, Abudu A, Johnson E, et al. (2018). The role of AP-1 in self-sufficient proliferation and migration of cancer cells and its potential impact on an autocrine/paracrine loop. Oncotarget 9:34259–78.
   PubMedGoogle Scholar
• Ignatova M, Yossifova L, Gardeva E, et al. (2011). Antiproliferative activity of nanofibers containing quaternized chitosan and/or doxorubicin against MCF7 human breast carcinoma cell line by apoptosis. J Bioactive Compat Polym 26:539–51. https://doi.org/10.1177/0883911511424655.
   Web of Science ®Google Scholar
• Islam F, Quadery TM, Bai R, et al. (2021). Novel pyrazolo[4,3-d]pyrimidine microtubule targeting agents (MTAs): synthesis, structure-activity relationship, in vitro and in vivo evaluation as antitumor agents. Bioorg Med Chem Lett 41:127923.
   PubMed Web of Science ®Google Scholar
• Jaragh Alhadad LA. (2021). Encapsulation and in vitro evaluation of low-density lipoprotein with cholesterol conjugated anti-HSP27 and HER2 proteins as drug delivery enhancement in ovarian cancer. BJSTR 35:27497–504.
   Google Scholar
• Jaragh-Alhadad L, Ali MS, Moustafa SM, et al. (2022a). Sulfonamide derivatives mediate breast and lung cancer cell line killing through tubulin inhibition. J Mol Struct 1268:133699.
   Web of Science ®Google Scholar
• Jaragh-Alhadad L, Samir M, Harford TJ, Karnik S. (2022b). Low-density lipoprotein encapsulated thiosemicarbazone metal complexes is active targeting vehicle for breast, lung, and prostate cancers. Drug Deliv 29:2206–16.
   PubMed Web of Science ®Google Scholar
• Jones J, Wang H, Karanam B, et al. (2014). Nuclear localization of Kaiso promotes the poorly differentiated phenotype and EMT in infiltrating ductal carcinomas. Clin Exp Metastasis 31:497–510. Epub 2014 Feb 26. PMID: 24570268.
   PubMed Web of Science ®Google Scholar
• Kader A, Davis PJ, Kara M, Liu H. (1998). Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles. J Control Release 55:231–43.
   PubMed Web of Science ®Google Scholar
• Kavinkumar T, Varunkumar K, Ravikumar V, Manivannan S. (2017). Anticancer activity of graphene oxide-reduced graphene oxide-silver nanoparticle composites. J Colloid Interface Sci 505:1125–33. Epub 2017 Jul 4. PMID: 28704918.
   PubMed Web of Science ®Google Scholar
• Kettler K, Veltman K, van de Meent D, et al. (2014). Cellular uptake of nanoparticles as determined by particle properties, experimental conditions, and cell type. Environ Toxicol Chem 33:481–92.
   PubMed Web of Science ®Google Scholar
• Komin A, Russell LM, Hristova KA, Searson PC. (2017). Peptide-based strategies for enhanced cell uptake, transcellular transport, and circulation: mechanisms and challenges. Adv Drug Deliv Rev 110-111:52–64.
   PubMed Web of Science ®Google Scholar
• Kuhn DA, Vanhecke D, Michen B, et al. (2014). Rothen-Rutishauser, B. Different endocytotic uptake mechanisms for nanoparticles in epithelial cells and macrophages. Beilstein J Nanotechnol 5:1625–36.
   PubMed Web of Science ®Google Scholar
• Laila AJA, Gamaleldin IH, Fars KA. (2022). Development of nimesulide analogs as a dual inhibitor targeting tubulin and HSP27 for treatment of female cancers. J Mol Struct 1248:131479. https://doi.org/10.1016/j.molstruc.2021.131479.
   Web of Science ®Google Scholar
• Lara-Ochoa S, Ortega-Lara W, Guerrero-Beltrán CE. (2021). Hydroxyapatite nanoparticles in drug delivery: physicochemistry and applications. Pharmaceutics 13:1642.
   PubMed Web of Science ®Google Scholar
• Lewandowska H, Kalinowska M. (2020). New polyphenol-containing LDL nano-preparations in oxidative stress and DNA damage: a potential route for cell-targeted PP delivery. Materials (Basel) 13:5106.
   PubMed Web of Science ®Google Scholar
• Lu CW, Lo YH, Chen CH, et al. (2017). VLDL and LDL, but not HDL, promote breast cancer cell proliferation, metastasis, and angiogenesis. Cancer Lett 388:130–8.
   PubMed Web of Science ®Google Scholar
• Mahmoud E, Karen LW. (2012). Design of polymeric nanoparticles for biomedical delivery applications. Chem. Soc. Rev 41:2545–61.
   PubMed Web of Science ®Google Scholar
• Mahmoudian M, Salatin S, Khosroushahi AY. (2018). Natural low- and high-density lipoproteins as mighty bio-nanocarriers for anticancer drug delivery. Cancer Chemother Pharmacol 82:371–82. https://doi.org/10.1007/s00280-018-3626-4
   PubMed Web of Science ®Google Scholar
• Maletínská L, Blakely EA, Bjornstad KA, et al. (2000). Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res 60:2300–3.
   PubMed Web of Science ®Google Scholar
• Nasser SMI, Ghada ME, Ali DA, Ibrahim AME. (2016). Medicinal attributes of pyrazolo[1,5-a]pyrimidine based scaffold derivatives targeting kinases as anticancer agents. Future J Pharma Sci 2:60–70. https://doi.org/10.1016/j.fjps.2016.08.004.
   Google Scholar
• Pal R, Chakraborty B, Nath A, et al. (2016). Noble metal nanoparticle-induced oxidative stress modulates tumor associated macrophages (TAMs) from an M2 to M1 phenotype: an in vitro approach. Int Immunopharmacol 38:332–41.
   PubMed Web of Science ®Google Scholar
• Pires LA, Hegg R, Freitas FR, et al. (2012). Effect of neoadjuvant chemotherapy on low-density lipoprotein (LDL) receptor and LDL receptor-related protein 1 (LRP-1) receptor in locally advanced breast cancer. Braz J Med Biol Res 45:557–64.
   PubMed Web of Science ®Google Scholar
• Radwan AA, Alanazi FK. (2014). Targeting cancer using cholesterol conjugates. Saudi Pharm J 22:3–16.
   PubMed Web of Science ®Google Scholar
• Sana S, Reddy VG, Srinivasa RT, et al. (2021). Cinnamide derived pyrimidine-benzimidazole hybrids as tubulin inhibitors: synthesis, in silico and cell growth inhibition studies. Bioorg Chem 110:104765.
   PubMed Web of Science ®Google Scholar
• Sangrajrang S, Denoulet P, Laing NM, et al. (1998). Association of estramustine resistance in human prostatic carcinoma cells with modified patterns of tubulin expression. Biochem Pharmacol 55:325–31.
   PubMed Web of Science ®Google Scholar
• Song H, Li Y, Lee J, et al. (2009). Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9. Cancer Res 69:879–86.
   PubMed Web of Science ®Google Scholar
• Song L, Li H, Sunar U, et al. (2007). Naphthalocyanine-reconstituted LDL nanoparticles for in vivo cancer imaging and treatment. Int J Nanomedicine 2:767–74.
   PubMed Web of Science ®Google Scholar
• Thaxton CS, Jonathan SR, Pratap CN, David PC. (2016). Lipoproteins and lipoprotein mimetics for imaging and drug delivery. Adv Drug Deliv Rev 106:116–31.
   PubMed Web of Science ®Google Scholar
• Theresa MA, Pieter RC. (2013). Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Delivery Rev 65:36–48. https://doi.org/10.1016/j.addr.2012.09.037.
   PubMed Web of Science ®Google Scholar
• Tian J, Xu S, Deng H, et al. (2017). Fabrication of self-assembled chitosan-dispersed LDL nanoparticles for drug delivery with a one-step green method. Int J Pharm 517:25–34.
   PubMedGoogle Scholar
• Torchilin VP. (2007). Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 24:1–16.
   PubMed Web of Science ®Google Scholar
• Tsumita T, Maishi N, Annan DA, et al. (2022). The oxidized-LDL/LOX-1 axis in tumor endothelial cells enhances metastasis by recruiting neutrophils and cancer cells. Int J Cancer 151:944–56.
   PubMed Web of Science ®Google Scholar
• Vitols S. (1991). Uptake of low-density lipoprotein by malignant cells–possible therapeutic applications. Cancer Cells 3:488–95.
   PubMed Web of Science ®Google Scholar
• Vitols S, Söderberg-Reid K, Masquelier M, et al. (1990). Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex. Br J Cancer 62:724–9.
   PubMed Web of Science ®Google Scholar
• Wang Z, Duan X, Lv Y, Zhao Y. (2019). Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers. Life Sci 239:117013.
   PubMed Web of Science ®Google Scholar
• Wang T, Rahimizadeh K, Veedu RN. (2020). Development of a novel DNA oligonucleotide targeting low-density lipoprotein receptor. Mol Ther Nucleic Acids 19:190–8.
   PubMedGoogle Scholar
• Xing R, Wang X, Zhang C, et al. (2011). Superparamagnetic magnetite nanocrystal clusters as potential magnetic carriers for the delivery of platinum anticancer drugs. J Mater Chem 21:11142–9.
   Web of Science ®Google Scholar
• Xiupeng W, Li X, Atsuo I, et al. (2016). Rod-shaped and fluorine-substituted hydroxyapatite free of molecular immunopotentiators stimulates anti-cancer immunity in vivo. Chem Commun (Camb) 52:7078–81.
   PubMed Web of Science ®Google Scholar
• Yao D, Zhou Y, Zhu L, et al. (2017). Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer. Eur J Med Chem 140:155–71.
   PubMed Web of Science ®Google Scholar
• Zhang M, Qin X, Xu W, et al. (2021). Engineering of a dual-modal phototherapeutic nanoplatform for single NIR laser-triggered tumor therapy. J Colloid Interface Sci 594:493–501.
   PubMed Web of Science ®Google Scholar
• Zhang M, Qin X, Zhao Z, et al. (2022). A self-amplifying nanodrug to manipulate the Janus-faced nature of ferroptosis for tumor therapy. Nanoscale Horiz 7:198–210.
   PubMed Web of Science ®Google Scholar
• Zhong MQ, Hongyan L, Hongzhe S, Kwokping H. (2002). Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54:561–87.
   PubMed Web of Science ®Google Scholar
• Zhou H, Guo W, Zhao Y, et al. (2014). MicroRNA-135a acts as a putative tumor suppressor by directly targeting very low density lipoprotein receptor in human gallbladder cancer. Cancer Sci 105:956–65.
   PubMed Web of Science ®Google Scholar
• Zhu QL, Zhou Y, Guan M, et al. (2014). Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy. Biomaterials 35:5965–76.
   PubMed Web of Science ®Google Scholar